Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Union Minister noted that heat stress contributes to a rise in both communicable diseases such as dengue and non-communicable conditions like cardiovascular disorder
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Subscribe To Our Newsletter & Stay Updated